Is tesamorelin legal in Australia? ARTG, TGA, FDA and WADA records

Is tesamorelin legal in Australia?

The public records give no single yes or no. A keyword search of the TGA's public ARTG page on 14 October 2026 returned no matching results for 'tesamorelin' or 'Egrifta', so no ARTG entry was found. The TGA says peptide products regulated as therapeutic goods must be included in the ARTG before they can be imported, manufactured, supplied, exported or advertised, and that some limited exceptions apply, such as a specific approval, authority or exemption under the legislation (TGA, How we regulate therapeutic peptide products, read 14 October 2026). The Poisons Standard question is held open: the Australian law hub states no status for tesamorelin in either direction, and this page does the same.

Legality has several parts, and each part has its own record: whether a product is on the register, how the substance is classed in the Poisons Standard, what a state or territory adds, and what a person does with it. The table below keeps those records apart. The Schedule 4 and Appendix D explainer shows how the two Poisons Standard lists work.

A plain yes or no would be easy to write and wrong to publish. A register entry describes a product. A schedule entry classifies a substance. Neither says anything about one person's circumstances.

Evidence limits

What do these legal records not tell you?

Two further limits apply. The WADA 2026 List is the edition read here, and this page did not open any later edition. The ARTG result is a keyword search of one public page, not a search of every register field, and a product listed under another name could be missed.

The FDA material is a United States record. A US approval is not an Australian one.

Is tesamorelin approved by the TGA?

No ARTG entry for tesamorelin was found, so no TGA approval of a tesamorelin product was found. The ARTG is the TGA's register of therapeutic goods. Its public search page returned 'There were no matching results' for tesamorelin and for Egrifta on 14 October 2026. A control search for semaglutide the same day returned 35 results, including an Ozempic pre-filled pen entry, ARTG ID 388180, so the search page was working. The result is a dated keyword search, not a legal ruling.

A keyword search can miss a product listed under another name. The TGA also says that, in limited circumstances, health practitioners may be able to access an unapproved therapeutic good for a patient through established access pathways (TGA, How we regulate therapeutic peptide products, read 14 October 2026).

The TGA's ARTG search page is public and shows the register's own results for the same two terms.

What is tesamorelin approved for by the FDA?

The FDA label for Egrifta SV lists its indication as the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy (label, section 1, DailyMed record updated 29 July 2026, read 14 October 2026). The label lists limits of use: long-term cardiovascular safety has not been established, tesamorelin is not indicated for weight loss management, and there are no data to support improved compliance with anti-retroviral therapies. The label gives 2010 as the year of initial US approval.

The Egrifta WR label, a later formulation revised in March 2025, lists the same indication and also gives 2010 as the year of initial US approval. A 2026 narrative review dates the first US approval to November 2010 and the WR formulation to March 2025 (Dominikowski et al., Frontiers in Endocrinology, 2026). The pivotal trials behind the approval are described on the study findings page.

The approval is a US decision about one medicine. The labels are public on DailyMed, the US National Library of Medicine's label database.

What half-life does the FDA label give for tesamorelin?

The Egrifta SV label reports a mean elimination half-life of 8 minutes in healthy subjects, from its pharmacokinetic summary, which states no participant number and says tesamorelin's pharmacokinetics in people with kidney or liver impairment, in children and in older adults have not been established (Egrifta SV label, section 12.3, DailyMed record updated 29 July 2026). The Egrifta WR label, a different formulation, reports a mean elimination half-life of 11 minutes in healthy subjects, with no participant number given in the passage read (Egrifta WR label, section 12.3, revised March 2025). A half-life of minutes describes how fast the molecule leaves the blood, not how long any effect lasts.

The Egrifta SV label also reports a mean volume of distribution of 4.8 L/kg in healthy subjects, with no participant number given in that section, and states that no formal metabolism studies have been performed in humans (Egrifta SV label, section 12.3).

The comparison page sets the tesamorelin label record beside the other peptides' records and states that the records reviewed do not support a like-for-like pharmacokinetic comparison.

Is tesamorelin on the WADA Prohibited List?

Yes, in sport. The World Anti-Doping Agency's 2026 Prohibited List, effective 1 January 2026, names tesamorelin in class S2.2.4, growth hormone releasing factors, as an example of a GHRH analogue, alongside CJC-1293, CJC-1295 and sermorelin. Class S2 is prohibited at all times, in and out of competition, and the List says all prohibited substances in S2 are non-Specified Substances (WADA 2026 Prohibited List, read 14 October 2026). The listing is a sport rule. It is separate from the ARTG and from the Poisons Standard, and it says nothing about everyday legality.

Sport Integrity Australia says that a Therapeutic Use Exemption is unlikely to be granted for an unregistered medicine, and that the athlete may then face an anti-doping rule violation. Its Peptides explained page does not name tesamorelin (Sport Integrity Australia, read 14 October 2026).

The WADA List is published as a PDF on the WADA site, linked above. Whether a particular test looks for tesamorelin is a laboratory question, not a rule question.

What has the TGA said about peptide products like tesamorelin?

The TGA's safety advisory of 13 April 2026 names BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295 as examples of unapproved peptide products and does not name tesamorelin. The advisory says these products have not been evaluated for safety, quality or effectiveness by the TGA. The TGA's peptide products page, last updated 23 September 2026, says many peptide products promoted online are unapproved therapeutic goods that may be unlawful to import, supply or advertise. The absence of a name is not a statement that tesamorelin products are approved.

The TGA also says that disclaimers such as 'research use only' or 'not for human use' do not change whether a product is regulated as a therapeutic good, and do not remove advertising, manufacture, import, export or supply obligations (TGA, How we regulate therapeutic peptide products, read 14 October 2026). The advisory adds that state and territory laws may impose additional controls on the sale, supply and possession of unapproved peptide products.

The peptide products page linked above is the place to check for updates.

Has the FDA acted on tesamorelin sold as a research chemical?

An FDA warning letter dated 24 August 2026 to a US online seller lists nine products, including 'Tesamorelin Research Peptide' and 'Tesamorelin Ipamorelin Blend', as unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act. The letter says that, despite labels reading 'for laboratory, research, and analytical use' and 'not intended for human or veterinary use', evidence obtained from the seller's website establishes that the products are intended to be drugs for human use (FDA warning letter 733652, 24 August 2026). It is a US enforcement record about one seller, and it carries no force in Australia.

The letter does not rule on any other seller or on research material in general. In this letter, the FDA relied on the seller's website and not only on the product labels. The TGA's statement that a research-use-only disclaimer does not change a product's status reaches a similar point in Australian terms.

The Australian law hub records the same letter in its account of FDA enforcement and sets tesamorelin beside the other catalogue peptides.

Does the approved medicine's legal record apply to research-use tesamorelin?

No. The FDA approval record belongs to Egrifta SV and Egrifta WR, which are medicines with labels and trial data. Research-use tesamorelin reference material is a laboratory compound, is not a medicine, is not a substitute for one, and is not for human or animal use. A research-use-only label does not change how a regulator classifies a product, as the TGA and FDA statements above both say. Nothing on this page states that any laboratory material is lawful or unlawful for any person.

This site's catalogue lists tesamorelin reference material as freeze-dried laboratory stock, with a historical sample report that covers only the sample it names. The same molecule on paper is not the same product in law.